Cardiological Parameters Predict Mortality and Cardiotoxicity in Oncological Patients
Authors' conclusion
In cancer patients, CVRF accumulation predicts cardiotoxicity whereas elevated hs-cTnT or NT-proBNP levels are associated with ACM.
Study context
- Population
- Patients with oncological diseases admitted to the Cardio-Oncology Unit, Heidelberg University Hospital, 2016–2020
- Participants
- 1,971 patients
- Exposure
- Cardiac biomarkers and patient-related risk factors as predictors of all-cause mortality (ACM) and cardiotoxicity
- Outcome
- ACM
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- ACM reached
- 490 patients (25.7%)
- Time to ACM, median [IQR]
- 363.5 [121.8, 522.5] days
- Hs-cTnT ≥ 7 ng/L as independent predictor of ACM, OR
- 1.82, P < 0.001
- N-terminal pro-brain natriuretic peptide (NT-proBNP) as independent predictor of ACM, OR
- 1.98, P < 0.001
- Reduced LVEF not associated with increased ACM
- P = 0.85
Observational data: associations, not effects.
Secondary outcomes
Cardiotoxicity (ESC definition)
- Cardiotoxicity reached
- 182 patients (9.2%)
- Time to cardiotoxicity, median [IQR]
- 793.5 [411.2, 1165.0] days
Multiple cardiovascular risk factors (CVRFs) (high risk, n = 886)
- Cardiotoxicity
- 100/886, 11.3%
- Cardiotoxicity, HR
- 1.57, P = 0.004
- Elevated baseline high-sensitivity cardiac troponin T (hs-cTnT), OR
- 1.60, P = 0.006
- Elevated baseline NT-proBNP, OR
- 4.00, P < 0.001
- ACM, OR
- 1.43, P = 0.031
Original publication
Cardiological Parameters Predict Mortality and Cardiotoxicity in Oncological Patients. ESC Heart Fail. Published 27 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →